As theranostic radiopharmaceuticals gain prevalence, companies must overcome associated regulatory, manufacturing and ...

The FDA's verdict on PTC's Translarna could spell the end for the drug's decades-long and tumultuous US DMD development ...

Lilly’s amassing of a $1.5bn pre-launch inventory follows sizeable investments into US manufacturing facilities.

As drug potency increases, OEB 6 containment is becoming increasingly crucial for safe HPAPI manufacturing, driven by oncology growth, and complex payloads.

Disc Medicine has received a CRL from the US FDA concerning its New Drug Application (NDA) for bitopertin for EPP.

The European Life Sciences Coalition (ELSC) aims to mobilise public and private investment amid concerns for the sector’s flagging funding landscape.

The ABPI says that UK industry and academia must come together to bridge the gap between academic and commercially ready preclinical models.

As pain is such a heterogeneous indication, significant opportunities remain for a variety of different and more effective non-opioid treatment options to be developed.

Ampersand Capital Partners has acquired Purna Pharmaceuticals, a Belgium based provider of development and manufacturing services for liquid and semi-solid dosage forms in the pharmaceutical sector.

Amgen has secured EC approval for Uplizna as an add-on treatment to standard therapy for adults with gMG who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive.

Every two years, South Korea adjusts the national health insurance (NHI) prices for existing listed products based on the ...

Outgoing Merck KGaA CEO Belén Garijo is set take the helm at Sanofi, after the French vaccine specialist announced it would not renew existing CEO Paul Hudson’s contract.